





**Series C
Investor Presentation**

Second Quarter 2024

 **Geneoscopy**
Transforming Gastrointestinal Health

©2024 Geneoscopy, Inc. All Rights Reserved.

A video inset on the right side of the slide shows a man with dark hair, wearing a blue blazer over a light blue shirt, speaking into a microphone. He is positioned in front of a blurred background that appears to be an office interior.



Geneoscopy's mission is to empower patients and providers to **transform gastrointestinal (GI) health** through innovative diagnostic tests that prevent, detect and monitor disease

© 2024 GENEOSCOPY, INC. 

The slide features a dark blue background with a large, stylized, light blue DNA double helix on the right side. A small video inset in the top right corner shows a man with dark hair, wearing a blue jacket over a white shirt, speaking. The text is white, with 'transform gastrointestinal (GI) health' in bold and light blue.

Our novel technology platform will transform GI health

Innovative Platform	Novel stool-derived eukaryotic RNA technology protected by a robust intellectual property portfolio
\$18B CRC screening opportunity	Technologically validated, clinically differentiated, and de-risked CRC screening assay with FDA approval and CMS coverage expected in 1H2024
Near-term commercial launch	Partnering with Labcorp , the largest laboratory provider, will provide the infrastructure, reach, and access for a scalable launch
Diversified pipeline	Comprehensive diagnostic platform for IBD disease management developed in partnership with biopharma
Capital efficient growth strategy	Cash flow breakeven anticipated within three years of commercial launch



Gastrointestinal diseases affect
1 in 4
Americans

Source: NIH

4 | PROPRIETARY AND CONFIDENTIAL


@2024 GENEOSCOPY, INC.

A large photograph of a diverse group of people, including an older man with a white beard and a woman, smiling. In the bottom right corner, there is a small inset video showing a man in a blue jacket speaking.

Geneoscopy's technology platform is built for GI health

Stool

SOURCE OF GI BIOMARKERS



RNA

PROVIDING UNIQUE INSIGHTS



Phenotypic
Quantitative and measurable
Real-time and dynamic

GENOSCOPY COMPETITIVE ADVANTAGE

IP Protection and Trade Secrets
for the testing of stool-derived eukaryotic RNA¹

¹ Geneoscopy granted patents include U.S. Patent No. 11,479,820, U.S. Patent No. 11,479,824, Japanese Patent No. 7109462, Australian Patent No. 2017348369, and Chinese Patent No. ZL20178006034.4

5 | PROPRIETARY AND CONFIDENTIAL © 2024 GENEOSCOPY, INC.

Exact Sciences Ex. 2021, Page 5 of 26

Our RNA approach provides a universal signal for disease detection



Opportunity to offer solutions for numerous unmet medical needs



Deploying our first commercial test in CRC screening market

110M

Average risk
individuals
age 45-85



\$18B

CRC screening
market

- ✓ Noninvasive stool-based tests are seeing rapid adoption
- ✓ 44M average risk individuals remain unscreened
- ✓ One large player in at-home stool testing, making this segment primed for a fast follower

Sources: U.S. Census data, Genescopy estimates (includes US markets only)

8 | PROPRIETARY AND CONFIDENTIAL



Colorectal cancer is the 2nd deadliest cancer worldwide



1 in 24
Diagnosed with CRC



63%
Diagnosed with late stage



>50K
Annual deaths in US

~70% of CRC-related deaths could be prevented through improved screening

Sources: American Cancer Society, cancer.net

9 | PROPRIETARY AND CONFIDENTIAL



Lack of convenience and aversion to colonoscopy drives low screening compliance

COLONOSCOPY LIMITATIONS

BOWEL PREP




SEDATION



DISCOMFORT



CANCER SCREENING COMPLIANCE RATES



44M

Unscreened
average risk
individuals
age 45-85

Sources: American Cancer Society National Colorectal Cancer Roundtable, National Cancer Institute, JAMA Network, Geneoscopy estimates



Noninvasive screening tests have seen rapid growth,
but opportunities remain for further market expansion



ANNUAL SALES AND VOLUME



Sources: SEC filings, Geneoscopy estimates

10%
Cologuard
Market share

Geneoscopy large
growth opportunity



Introducing ColoSense™ – Geneoscopy's first commercial test

COLOSENSE
LIKE NO OTHER



Best-in-class performance

Highest sensitivity of a noninvasive CRC screening test from a prospective registrational clinical study



De-risked path to launch

On track for FDA-approval and CMS coverage in 1H 2024, ahead of launch in 3Q 2024




Commercial partner for scale

Multi-year Labcorp agreement will provide extensive patient and provider access at launch

RNA approach best addresses CRC screening in younger individuals

RNA sensitivity is consistent, while DNA sensitivity improves with age



CRC screening has become increasingly important for younger individuals

- ✓ Lowering the screening age added over 20 million individuals to the average risk screening population
- ✓ More than 40% of the screening-eligible population are individuals under the age of 50
- ✓ Individuals under the age of 55 are ~60% more likely to be diagnosed with late-stage disease
- ✓ Since 1994, CRC incidence among individuals under the age of 50 has increased by 51%

Sources: JNCI, American Cancer Society, FDA, Cancer Prevention Research, ColoSense (Barnwell et al, JAMA, 2023), Cologuard (P130017.SSED), Cologuard+ (Imperiale et al, NEJM, 2024)
Note: Head-to-head study not completed. Clinical data are from independent, peer-reviewed studies



JAMA publication highlights strong clinical performance




Representative study cohort testing the full range of average-risk screening population (45 – 85 years)



Robust sensitivity for CRC (94%) and AA (46%) the highest reported in a registrational study




RNA preserves high sensitivity for CRC (100%) and AA (45%) in 45 to 49 age group




ColoSense™ will be the most sensitive non-invasive CRC screening test

COLORECTAL CANCER SENSITIVITY





ADVANCED ADENOMA / APL SENSITIVITY



Sources: ColoSense (Barnell et al. JAMA, 2023), Cologuard+/FIT (Imperiale et al. NEJM, 2024), Shield (Chung et al. NEJM, 2024), Internal Market Research

De-risked pathway for FDA approval and CMS coverage ahead of commercial launch in 1H2024





Labcorp collaboration provides infrastructure for efficient growth...



...through extensive patient and provider access

 >90% US lives contracted in-network	 1,000+ primary care sales representatives	 Leading national provider of FIT screening	 >90% orders received electronically
 160M+ annual patient interactions	 600M+ tests performed annually	 4,000+ hospital system integrations	 45B+ lab results in proprietary data sets

 **labcorp** OUR MISSION: Improve health, improve lives

19 | PROPRIETARY AND CONFIDENTIAL



Key growth drivers for ColoSense

1

Superior sensitivity, with significant differentiation in the 45–49 age group, driven by RNA approach

2

Integration into Labcorp's best-in-class infrastructure for laboratory test adoption and a seamless patient/provider experience

3

Continued growth of overall market and further penetration of non-invasive screening tests



Lack of noninvasive testing solutions creates opportunity

Fecal calprotectin (stool-protein) and c-reactive protein (blood-protein) are the most commonly-used inflammatory markers, but lack the accuracy for clinicians to improve the current standard of care



DIAGNOSIS

>50% of patients are misdiagnosed before receiving an IBD diagnosis



PROGNOSIS

No validated methods to predict flares or identify patients with high-risk phenotypes (e.g., stricturing)



THERAPEUTIC SELECTION

No validated methods for precision medicine or data-driven approaches to dictate treatment



PATIENT MONITORING

Colonoscopy and patient surveys are the primary methods for assessing disease activity



Our technology is already addressing these critical unmet needs...

Extensive Pharma Activity

Anti-IL 12/23 Agents    	JAK Inhibitors   
Anti-TNF Agents    	Anti-Integrin Inhibitor  S1P1 Modulator 
35+ Additional Drugs in Phase I-III Development	

Geneoscopy Advantage

R_x

THERAPEUTIC SELECTION

seRNA signature used to identify and enrich treatment population for likely responders






PATIENT MONITORING

seRNA signature used to noninvasively measure mucosal healing and impact of treatment




...with numerous brand-name partnerships already showing promise and others expected to launch in 2024

Target of Intent/MOA	 TYK2	 MRP2/FPR1	 TL1A	 α 4 β 7 Integrin	 Undisclosed
Target of Intent/MOA	 Undisclosed	 Undisclosed	 Undisclosed	 Undisclosed	 Hyperbaric Oxygen

Geneoscopy is building the most expansive IBD database that will drive product development for companion diagnostics (CDx) and in-vitro diagnostics (IVD)

Note: This slide is a representative example and does not make warrants or representation to these companies and targets



Vision to become the leader in GI health diagnostics

CRC	IBD	Other Unmet Needs
ColoSense™ 2.0 2 nd generation CRC screening test with enhanced sensitivity profile	Precision Medicine Clinical assays to assist with therapy selection Disease Management Clinical assays to monitor patients noninvasively	Lynch Syndrome / FAP Celiac Disease Irritable Bowel Syndrome

Geneoscopy is Transforming Gastrointestinal Health

25 | PROPRIETARY AND CONFIDENTIAL

@2024 GENEOSCOPY, INC.



Geneoscopy possesses extensive experience developing and commercializing transformational diagnostics products





LEADERSHIP TEAM

 Andrew Barnell, MBA Chief Executive Officer	 Erica Barnell, MD/PhD Chief Medical / Science Officer	 Matt Sargent Chief Commercial Officer
 Julie LaRocca, MS SVP, Quality / Regulatory	 Jim Fitzgibbon, MBA VP, Bus Dev / BioPharma Partnering	 Ryan Gorman VP, Sales
 Gary Gallimore SVP, Software / IT	 Jeff Salzman, MHM VP, Market Access	 Tyler Aldredge VP, Operations

ADVISORS

 Don Hardison Board of Directors Chairman	 David Lieberman, MD/AGAF CRC Advisory Board Chairman	 Matt Ciorba, MD IBD Advisory Board Chairman
---	---	--

EXPERIENCE

KEY INVESTORS